Acute management of migraine
- PMID: 21049703
Acute management of migraine
Abstract
Migraine is a brain disease whose principal symptom is episodic intense throbbing pain in the head which is often accompanied by photophobia, phonophobia, nausea and vomiting. Primary objectives of migraine treatment are to abort the acute attacks, treat associated symptoms and prevent future attacks. With a majority of migraine patients being young, they will need a treatment plan to suit their professional work, leisure and reproductive concerns. Non specific anti-migraine drugs like non-steroidal anti-inflammatory drugs, anti-emetics, narcotics, and sympathomimetics are usually helpful in mild to moderate attacks. Specific drugs like triptans and ergots are useful for moderate to severe attacks. In step care approach, the patients are started with the simplest options like simple analgesics first followed by non-steroidal agents, then ergot preparations and eventually triptans if they do not respond. In stratified care approach, the attacks and the patients are stratified according to the severity and therapeutic response. Those with severe disabling episodes are given specific anti-migraine medications like triptans whereas patients with mild or low disability are treated with simple analgesics. Currently, the most favored acute anti-migraine medication is a triptan. At marketed doses all triptans are effective as compared to placebos and generally well tolerated. Amongst them however, rizatriptan 10 mg, eletriptan 80 mg and almotriptan 12.5 mg provide the highest likelihood of consistent success. Triptan related adverse events are usually short lived, mild and clinically insignificant. Ergots are slowly being replaced by triptans. This is because of their adverse side-effects, low bioavailability and high potential for abuse that can lead to overuse headache.
Similar articles
-
Migraine: diagnosis, management, and new treatment options.Am J Manag Care. 2002 Feb;8(3 Suppl):S58-73. Am J Manag Care. 2002. PMID: 11859906 Review.
-
Almotriptan in triptan-naïve patients: new evidence of benefits.Cephalalgia. 2008 Sep;28 Suppl 2:14-20. doi: 10.1111/j.1468-2982.2008.01686.x. Cephalalgia. 2008. PMID: 18715328 Review.
-
Long-term efficacy and tolerability of rizatriptan wafers in migraine.MedGenMed. 2001 Jun 1;3(3):1. MedGenMed. 2001. PMID: 11549974 Clinical Trial.
-
[Treatment guidelines for acute migraine attacks].Acta Neurol Taiwan. 2007 Dec;16(4):251-68. Acta Neurol Taiwan. 2007. PMID: 18220021 Chinese.
-
[The role of triptans and analgesics for primary headache treatment].Nihon Rinsho. 2005 Oct;63(10):1797-801. Nihon Rinsho. 2005. PMID: 16218393 Review. Japanese.
Cited by
-
A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.Adv Ther. 2021 Oct;38(10):5087-5097. doi: 10.1007/s12325-021-01781-z. Epub 2021 May 31. Adv Ther. 2021. PMID: 34057676 Free PMC article. Review.
-
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.Clin Transl Sci. 2020 May;13(3):462-472. doi: 10.1111/cts.12728. Epub 2020 Jan 3. Clin Transl Sci. 2020. PMID: 31899602 Free PMC article. Clinical Trial.